Publikationen, an denen er mitarbeitet Marc Miravitlles (41)

2024

  1. Detection of Alpha-1 Antitrypsin Levels in Chronic Obstructive Pulmonary Disease in Respiratory Clinics in Spain: Results of the EPOCONSUL 2021 Audit

    Journal of Clinical Medicine, Vol. 13, Núm. 4

2023

  1. Characteristics of individuals with alpha-1 antitrypsin deficiency from Northern and Southern European countries: EARCO international registry

    The European respiratory journal

  2. Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry (Respiratory Research, (2022), 23, 1, (352), 10.1186/s12931-022-02275-4)

    Respiratory Research

  3. Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin

    International Journal of COPD, Vol. 18, pp. 1691-1700

  4. Variations in Chronic Obstructive Pulmonary Disease Outpatient Care in Respiratory Clinics: Results From the 2021 EPOCONSUL Audit

    Archivos de Bronconeumologia, Vol. 59, Núm. 5, pp. 295-304

2022

  1. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry

    Respiratory Research, Vol. 23, Núm. 1

  2. Demographic and clinical characteristics of patients with α1-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO

    ERJ Open Research, Vol. 8, Núm. 3

  3. Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey

    International Journal of COPD, Vol. 17, pp. 1577-1587

2021

  1. Burden of disease among exacerbating patients with COPD treated with triple therapy in Spain

    International Journal of COPD, Vol. 16, pp. 2149-2161

2020

  1. Prevalence of α1-antitrypsin pizz genotypes in patients with copd in Europe: A systematic review

    European Respiratory Review, Vol. 29, Núm. 157, pp. 1-7

  2. Relationship between clinical control, respiratory symptoms and quality of life for patients with COPD

    International Journal of COPD, Vol. 15, pp. 2683-2693

  3. The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency

    COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 17, Núm. 4, pp. 346-354

2019

  1. Correction: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: A Spanish National Healthcare System perspective (Respiratory Research (2018) 19 (224) DOI: 10.1186/s12931-018-0916-7)

    Respiratory Research

  2. Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps

    The European respiratory journal

  3. Geographic distribution of chronic obstructive pulmonary disease prevalence in Africa, Asia and Australasia

    International Journal of Tuberculosis and Lung Disease, Vol. 23, Núm. 10, pp. 1100-1106

  4. Patients with Chronic Obstructive Pulmonary Disease Exacerbations: Recommendations for Diagnosis, Treatment and Care

    Archivos de Bronconeumologia, Vol. 55, Núm. 9, pp. 478-487

2018

  1. Alpha-1 antitrypsin deficiency: Outstanding questions and future directions

    Orphanet Journal of Rare Diseases, Vol. 13, Núm. 1

  2. Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD

    Respiratory Medicine, Vol. 136, pp. 8-14

  3. Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus

    Pulmonary Pharmacology and Therapeutics, Vol. 48, pp. 97-103

  4. Geographical Distribution of COPD Prevalence in the Americas

    COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 15, Núm. 4, pp. 317-325